Methicillin-resistant Staphylococcus aureus infections: A review of the currently available treatment options

Journal of Global Antimicrobial Resistance

Volumn 7, Issue , 2016, Pages 178-186

  Purrello, S M ^a   Garau, J ^b   Giamarellos, E ^c   Mazzei, T ^d   Pea, F ^e,f   Soriano, A ^g   Stefani, S ^a  

^a UNIVERSITY OF CATANIA   (Italy)

^b HOSPITAL MÚTUA DE TERRASSA   (Spain)

^c NATIONAL AND KAPODISTRIAN UNIVERSITY OF ATHENS   (Greece)

^d UNIVERSITY OF FLORENCE   (Italy)

^e SANTA MARIA DELLA MISERICORDIA UNIVERSITY HOSPITAL   (Italy)

^f UNIVERSITY OF UDINE   (Italy)

^g HOSPITAL CLÍNIC   (Spain)

Author keywords

Antibiotics; MRSA infection; Treatment

Indexed keywords

ANTIBIOTIC AGENT; CEPHALOSPORIN DERIVATIVE; DAPTOMYCIN; LINEZOLID; LIPOGLYCOPEPTIDE; OXAZOLIDINONE DERIVATIVE; PEPTIDE DERIVATIVE; UNCLASSIFIED DRUG; VANCOMYCIN; ANTIINFECTIVE AGENT;

ANTIBIOTIC THERAPY; BACTERIAL ENDOCARDITIS; BLOODSTREAM INFECTION; BONE AND JOINT INFECTIONS; DRUG USE; HOSPITAL ASSOCIATED PNEUMONIA; HOSPITAL INFECTION; HUMAN; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS INFECTION; NONHUMAN; PNEUMONIA; PRIORITY JOURNAL; REVIEW; SKIN INFECTION; SOFT TISSUE INFECTION; VENTILATOR ASSOCIATED PNEUMONIA; DRUG EFFECT; STAPHYLOCOCCUS INFECTION;

ANTI-BACTERIAL AGENTS; DAPTOMYCIN; HUMANS; LINEZOLID; METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS; STAPHYLOCOCCAL INFECTIONS; VANCOMYCIN;

EID: 85000839133     PISSN: 22137165     EISSN: 22137173     Source Type: Journal    
DOI: 10.1016/j.jgar.2016.07.010     Document Type: Review

References (122)

1. [1] Rodvold, K.A., McConeghy, K.W., Methicillin-resistant Staphylococcus aureus therapy: past, present and future. Clin Infect Dis 58:Suppl. 1 (2014), S20–6.
2. [2] Gould, I.M., David, M.Z., Esposito, S., Garau, J., Lina, G., Mazzei, T., et al. New insights into methicillin-resistant Staphylococcus aureus pathogenesis, treatment and resistance. Int J Antimicrob Agents 39 (2012), 96–104.
3. [3] Stryewski, M.E., Corey, G.R., Methicillin-resistant Staphylococcus aureus: an evolving pathogen. Clin Infect Dis 58:Suppl. 1 (2014), S10–9.
4. [4] US Centers for Disease Control and Prevention, Active bacterial core surveillance (ABCs) report, emerging infections program network, methicillin-resistant Staphylococcus aureus, 2012., 2012, CDC, Atlanta, GA http://www.cdc.gov/abcs/reports-findings/survreports/mrsa12.pdf [accessed 16.08.16].
5. [5] Bassetti, M., Baguneid, M., Bouza, E., Dryden, M., Nathwani, D., Wilcox, M., European perspective and update on the management of complicated skin and soft tissue infections due to methicillin-resistant Staphylococcus aureus after more than 10 years of experience with linezolid. Clin Microbiol Infect 20:Suppl. 4 (2014), 3–18.
6. [6] Gould, I.M., Gauda, R., Esposito, S., Gudiol, F., Mazzei, T., Garau, J., Management of serious methicillin-resistant Staphylococcus aureus infection: what are the limits?. Int J Antimicrob Agents 37 (2011), 202–209.
7. [7] Schilling, A., Neuner, E., Rehm, S.J., Vancomycin: a 50-something-year-old antibiotic we still don't understand. Cleve Clin J Med 78 (2011), 465–471.
8. [8] Holmes, N.E., Tong, S.Y., Davis, J.S., Hal, S.J., Treatment of methicillin-resistant Staphylococcus aureus: vancomycin and beyond. Semin Respir Crit Care Med 36 (2015), 17–30.
9. [9] Liu, C., Bayer, A., Cosgrove, S.E., Daum, R.S., Fridkin, S.K., Gorwitz, R.J., et al. Clinical practice guidelines by the Infectious Diseases Society of America for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children. Clin Infect Dis 52 (2011), e18–e55 Erratum in: Clin Infect Dis 2011;53:319.
10. [10] Campanile, F., Borbone, S., Perez, M., Bongiorno, D., Cafiso, V., Bertuccio, T., et al. Heteroresistance to glycopeptides in Italian methicillin-resistant Staphylococcus aureus (MRSA) isolates. Int J Antimicrob Agents 36 (2010), 415–419.
11. [11] Khatib, R., Jose, J., Musta, A., Sharma, M., Fakih, M.G., Johnson, L.B., et al. Relevance of vancomycin-intermediate susceptibility and heteroresistance in methicillin-resistant Staphylococcus aureus bacteraemia. J Antimicrob Chemother 66 (2011), 1594–1599.
12. [12] Satola, S.W., Lessa, F.C., Ray, S.M., Bulens, S.N., Lynfield, R., Schaffner, W., et al. Clinical and laboratory characteristics of invasive infections due to methicillin-resistant Staphylococcus aureus isolates demonstrating a vancomycin MIC of 2 micrograms per milliliter: lack of effect of heteroresistant vancomycin-intermediate S. aureus phenotype. J Clin Microbiol 49 (2011), 1583–1587.
13. [13] Horne, K.C., Howden, B.P., Grabsch, E.A., Graham, M., Ward, P.B., Xie, S., et al. Prospective comparison of the clinical impacts of heterogeneous vancomycin-intermediate methicillin-resistant Staphylococcus aureus (MRSA) and vancomycin-susceptible MRSA. Antimicrob Agents Chemother 53 (2009), 3447–3452.
14. [14] Bae, I.G., Federspiel, J.J., Miró, J.M., Woods, C.W., Park, L., Rybak, M.J., et al. Heterogeneous vancomycin-intermediate susceptibility phenotype in bloodstream methicillin-resistant Staphylococcus aureus isolates from an international cohort of patients with infective endocarditis: prevalence, genotype, and clinical significance. J Infect Dis 200 (2009), 1355–1366.
15. [15] Howden, B.P., Ward, P.B., Charles, P.G., Korman, T.M., Fuller, A., du Cros, P., et al. Treatment outcomes for serious infections caused by methicillin-resistant Staphylococcus aureus with reduced vancomycin susceptibility. Clin Infect Dis 38 (2004), 521–528.
16. [16] Edwards, B., Milne, K., Lawes, T., Cook, I., Robb, A., Gould, I.M., Is vancomycin ‘MIC creep’ method dependent? Analysis of methicillin-resistant Staphylococcus aureus susceptibility trends in blood isolates from North East Scotland from 2006 to 2010. J Clin Microbiol 50 (2012), 318–325.
17. [17] Kalil, A.C., Van Schooneveld, T.C., Fey, P.D., Rupp, M.E., Association between vancomycin minimum inhibitory concentration and mortality among patients with Staphylococcus aureus bloodstream infections: a systematic review and meta-analysis. JAMA 312 (2014), 1552–1564.
18. [18] Cafiso, V., Bertuccio, T., Spina, D., Purrello, S., Campanile, F., Di Pietro, C., et al. Modulating activity of vancomycin and daptomycin on the expression of autolysis cell-wall turnover and membrane charge genes in hVISA and VISA strains. PLoS One, 7, 2012, e29573.
19. [19] Ludwig, F., Edwards, B., Lawes, T., Gould, I.M., Effects of storage on vancomycin and daptomycin MIC in susceptible blood isolates of methicillin-resistant Staphylococcus aureus. J Clin Microbiol 50 (2012), 3383–3387.
20. [20] Vandecasteele, S.J., De Vriese, A.S., Tacconelli, E., The pharmacokinetics and pharmacodynamics of vancomycin in clinical practice: evidence and uncertainties. J Antimicrob Chemother 68 (2013), 743–748.
21. [21] Bradley, J.S., Which antibiotic for resistant Gram-positives, and why?. J Infect 68:Suppl. 1 (2014), S63–75.
22. [22] Wu, G., Abraham, T., Rapp, J., Vastey, F., Saad, N., Balmir, E., Daptomycin: evaluation of a high-dose treatment strategy. Int J Antimicrob Agents 38 (2011), 192–196.
23. [23] Fenton, C., Keating, G.M., Curran, M.P., Daptomycin. Drugs 64 (2004), 445–455.
24. [24] Gould, I.M., Miró, J.M., Rybak, M.J., Daptomycin: the role of high-dose and combination therapy for Gram-positive infections. Int J Antimicrob Agents 42 (2013), 202–210.
25. [25] Liu, C., Bayer, A., Cosgrove, S.E., Daum, R.S., Fridkin, S.K., Gorwitz, R.J., et al. Clinical practice guidelines by the Infectious Diseases Society of America for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children: executive summary. Clin Infect Dis 52 (2011), 285–292.
26. [26] Kullar, R., Davis, S.L., Levine, D.P., Zhao, J.J., Crank, C.W., Segreti, J., et al. High-dose daptomycin for treatment of complicated Gram-positive infections: a large, multicenter, retrospective study. Pharmacotherapy 31 (2011), 527–536.
27. [27] Benvenuto, M., Benziger, D.P., Yankelev, S., Vigliani, G., Pharmacokinetics and tolerability of daptomycin at doses up to 12 milligrams per kilogram of body weight once daily in healthy volunteers. Antimicrob Agents Chemother 50 (2006), 3245–3249.
28. [28] Moise, P.A., Hershberger, E., Amodio-Groton, M.I., Lamp, K.C., Safety and clinical outcomes when utilizing high-dose (≥8 mg/kg) daptomycin therapy. Ann Pharmacother 43 (2009), 1211–1219.
29. [29] Patel, N., Lubanski, P., Ferro, S., Bonafede, M., Harrington, S., Evans, A., et al. Correlation between vancomycin MIC values and those of other agents against Gram-positive bacteria among patients with bloodstream infections caused by methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother 53 (2009), 5141–5144.
30. [30] Mishra, N.N., Bayer, A.S., Weidenmaier, C., Grau, T., Wanner, S., Stefani, S., et al. Phenotypic and genotypic characterization of daptomycin-resistant methicillin-resistant Staphylococcus aureus strains: relative roles of mprF and dlt operons. PLoS One, 9, 2014, e107426.
31. [31] Cafiso, V., Bertuccio, T., Purrello, S., Campanile, F., Mammina, C., Sartor, A., et al. dltA overexpression: a strain-independent keystone of daptomycin resistance in methicillin-resistant Staphylococcus aureus. Int J Antimicrob Agents 43 (2014), 26–31.
32. [32] Stefani, S., Campanile, F., Santagati, M., Mezzatesta, M.L., Cafiso, V., Pacini, G., Insights and clinical perspectives of daptomycin resistance in Staphylococcus aureus: a review of the available evidence. Int J Antimicrob Agents 46 (2015), 278–289.
33. [33] Barber, K.E., Ireland, C.E., Bukavyn, N., Rybak, M.J., Observation of ‘seesaw effect’ with vancomycin, teicoplanin, daptomycin and ceftaroline in 150 unique MRSA strains. Infect Dis Ther 3 (2014), 35–43.
34. [34] Werth, B.J., Steed, M.E., Kaatz, G.W., Rybak, M.J., Evaluation of ceftaroline activity against heteroresistant vancomycin-intermediate Staphylococcus aureus and vancomycin-intermediate methicillin-resistant S. aureus strains in an in vitro pharmacokinetic/pharmacodynamic model: exploring the ‘seesaw effect’. Antimicrob Agents Chemother 57 (2013), 2664–2668.
35. [35] Mehta, S., Singh, C., Plata, K.B., Chanda, P.K., Paul, A., Riosa, S., et al. β-Lactams increase the antibacterial activity of daptomycin against clinical methicillin-resistant Staphylococcus aureus strains and prevent selection of daptomycin-resistant derivatives. Antimicrob Agents Chemother 56 (2012), 6192–6200.
36. [36] Rose, W.E., Schulz, L.T., Andes, D., Striker, R., Berti, A.D., Hutson, P.R., et al. Addition of ceftaroline to daptomycin after emergence of daptomycin-nonsusceptible Staphylococcus aureus during therapy improves antibacterial activity. Antimicrob Agents Chemother 56 (2012), 5296–5302.
37. [37] Bounthavong, M., Zargarzadeh, A., Hsu, D.I., Vanness, D.J., Cost-effectiveness analysis of linezolid, daptomycin, and vancomycin in methicillin-resistant Staphylococcus aureus: complicated skin and skin structure infection using Bayesian methods for evidence synthesis. Value Health 14 (2011), 631–639.
38. [38] Leone, S., Noviello, S., Boccia, G., De Caro, F., Esposito, S., Methicillin-resistant Staphylococcus aureus infections: role of daptomycin/β-lactams combination. Infez Med 23 (2015), 99–104.
39. [39] Stalker, D.J., Jungbluth, G.L., Clinical pharmacokinetics of linezolid, a novel oxazolidinone antibacterial. Clin Pharmacokinet 42 (2003), 1129–1140.
40. [40] Pea, F., Viale, P., Cojutti, P., Del Pin, B., Zamparini, E., Furlanut, M., Therapeutic drug monitoring may improve safety outcomes of long-term treatment with linezolid in adult patients. J Antimicrob Chemother 67 (2012), 2034–2042.
41. [41] Pharmacia Ltd, ZYVOX 600 mg film-coated tablets [summary of product characteristics]. 2011, Sandwich, UK, Pharmacia Ltd.
42. [42] Itani, K.M., Dryden, M.S., Bhattacharyya, H., Kunkel, M.J., Baruch, A.M., Weigelt, J.A., Efficacy and safety of linezolid versus vancomycin for the treatment of complicated skin and soft-tissue infections proven to be caused by methicillin-resistant Staphylococcus aureus. Am J Surg 199 (2010), 804–816.
43. [43] Chavanet, P., The ZEPHyR study: a randomized comparison of linezolid and vancomycin for MRSA pneumonia. Med Mal Infect 43 (2013), 451–455.
44. [44] Wu, V., Wang, Y.T., Wang, C.Y., Tsai, I., Wu, K.D., Hwang, J.J., et al. High frequency of linezolid-associated thrombocytopenia and anemia among patients with end-stage renal disease. Clin Infect Dis 42 (2006), 66–72.
45. [45] Meka, V.G., Pillai, S.K., Sakoulas, G., Wennersten, C., Venkataraman, L., DeGirolami, P.C., et al. Linezolid resistance in sequential Staphylococcus aureus isolates associated with a T2500A mutation in the 23S rRNA gene and loss of a single copy of rRNA. J Infect Dis 190 (2004), 311–317.
46. [46] Toh, S.M., Xiong, L., Arias, C.A., Villegas, M.V., Lolans, K., Quinn, J., et al. Acquisition of a natural resistance gene renders a clinical strain of methicillin-resistant Staphylococcus aureus resistant to the synthetic antibiotic linezolid. Mol Microbiol 64 (2007), 1506–1514.
47. [47] Barriere, S.L., The ATTAIN trials: efficacy and safety of telavancin compared with vancomycin for the treatment of hospital-acquired and ventilator-associated bacterial pneumonia. Future Microbiol 9 (2014), 281–289.
48. [48] Mendes, R.E., Sader, H.S., Farrell, D.J., Jones, R.N., Worldwide appraisal and update (2010) of telavancin activity tested against a collection of Gram-positive clinical pathogens from five continents. Antimicrob Agents Chemother 56 (2012), 3999–4004.
49. [49] Leonard, S.N., Szeto, Y.G., Zolotarev, M., Grigoryan, I.V., Comparative in vitro activity of telavancin, vancomycin and linezolid against heterogeneously vancomycin-intermediate Staphylococcus aureus (hVISA). Int J Antimicrob Agents 37 (2011), 558–561.
50. [50] Torres, A., Rubinstein, E., Corey, G.R., Stryjewski, M.E., Barriere, S.L., Analysis of phase 3 telavancin nosocomial pneumonia data excluding patients with severe renal impairment and acute renal failure. J Antimicrob Chemother 69 (2014), 1119–1126.
51. [51] Jones, R.N., Sader, H.S., Flamm, R.K., Update of dalbavancin spectrum and potency in the USA: report from the SENTRY Antimicrobial Surveillance Program (2011). Diagn Microbiol Infect Dis 75 (2013), 304–307.
52. [52] Dunne, M.W., Puttagunta, S., Giordano, P., Krievins, D., Zelasky, M., Baldassarre, J., A randomized clinical trial of single-dose versus weekly dalbavancin for treatment of acute bacterial skin and skin structure infection. Clin. Infect. Dis. 62:March (5) (2016), 545–551.
53. [53] Citron, D.M., Tyrrell, K.L., Goldstein, E.J., Comparative in vitro activities of dalbavancin and seven comparator agents against 41 Staphylococcus species cultured from osteomyelitis infections and 18 VISA and hVISA strains. Diagn Microbiol Infect Dis 79 (2014), 438–440.
54. [54] Boucher, H.W., Wilcox, M., Talbot, G.H., Puttagunta, S., Das, A.F., Dunne, M.W., Once-weekly dalbavancin versus daily conventional therapy for skin infection. N Engl J Med 370 (2014), 2169–2179.
55. [55] Esposito, S., Noviello, S., Leone, S., Dalbavancin for the treatment of acute bacterial skin and skin structure infections. Infez Med 23 (2015), 313–317.
56. [56] Ambrose, P.G., Drusano, G.L., Craig, W.A., In vivo activity of oritavancin in animal infection models and rationale for a new dosing regimen in humans. Clin Infect Dis 54:Suppl. 3 (2012), S220–S228.
57. [57] Arhin, F.F., Moeck, G., Draghi, D.C., Pillar, C.M., Sahm, D.F., Longitudinal analysis of the in vitro activity profile of oritavancin and comparator glycopeptides against Gram-positive organisms from Europe: 2005–2008. Int J Antimicrob Agents 36 (2010), 474–476.
58. [58] Lin, G., Pankuch, G., Appelbaum, P.C., Kosowska-Shick, K., Antistaphylococcal activity of oritavancin and its synergistic effect in combination with other antimicrobial agents. Antimicrob Agents Chemother 58 (2014), 6251–6254.
59. [59] Corey, G.R., Good, S., Jiang, H., Moeck, G., Wikler, M., Green, S., et al. Single-dose oritavancin versus 7–10 days of vancomycin in the treatment of Gram-positive acute bacterial skin and skin structure infections: the SOLO II noninferiority study. Clin Infect Dis 60 (2015), 254–262.
60. [60] Corey, G.R., Kabler, H., Mehra, P., Gupta, S., Overcash, J.S., Porwal, A., et al. Single-dose oritavancin in the treatment of acute bacterial skin infections. N Engl J Med 370 (2014), 2180–2190.
61. [61] Muller, A.E., Punt, N., Mouton, J.W., Exposure to ceftobiprole is associated with microbiological eradication and clinical cure in patients with nosocomial pneumonia. Antimicrob Agents Chemother 58 (2014), 2512–2519.
62. [62] El Solh, A., Ceftobiprole: a new broad spectrum cephalosporin. Expert Opin Pharmacother. 10:10 (2009), 1675–1686.
63. [63] Pillar, C.M., Aranza, M.K., Shah, D., Sahm, D.F., In vitro activity profile of ceftobiprole, an anti-MRSA cephalosporin, against recent gram-positive and gram-negative isolates of European origin. J Antimicrob. Chemother. 61:3 (2008), 595–602.
64. [64] Liapikou, A., Cillóniz, C., Torres, A., Ceftobiprole for the treatment of pneumonia: a European perspective. Drug Des. Devel. Ther. 18:August (9) (2015), 4565–4572.
65. [65] Farrell, D.J., Flamm, R.K., Sader, H.S., Jones, R.N., Ceftobiprole activity against over 60,000 clinical bacterial pathogens isolated in Europe, Turkey, and Israel from 2005 to 2010. Antimicrob. Agents Chemother. 58:7 (2014), 3882–3888.
66. [66] Rossolini, G.M., Dryden, M.S., Kozlov, R.S., Quintana, A., Flamm, R.K., Läuffer, J.M., Lee, E., Morrissey, I., CLASS Study Group, Comparative activity of ceftobiprole against Gram-positive and Gram-negative isolates from Europe and the Middle East: the CLASS study. J. Antimicrob. Chemother. 66:1 (2011), 151–159.
67. [67] Awad, S.S., Rodriguez, A.H., Chuang, Y.C., Marjanek, Z., Pareigis, A.J., Reis, G., et al. A phase 3 randomized double-blind comparison of ceftobiprole medocaril versus ceftazidime plus linezolid for the treatment of hospital-acquired pneumonia. Clin Infect Dis 59 (2014), 51–61.
68. [68] European Medicines Agency, European public assessment report (EPAR) for Zinforo., 2016, EMA, London, UK http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/002252/human_med_001584.jsp&mid=WC0b01ac058001d124 [accessed 02.01.16].
69. [69] Friedland, H.D., O'Neal, T., Biek, D., Eckburg, P.B., Rank, D.R., Llorens, L., et al. CANVAS 1 and 2: analysis of clinical response at Day 3 in two phase 3 trials of ceftaroline fosamil versus vancomycin plus aztreonam in treatment of acute bacterial skin and skin structure infections. Antimicrob Agents Chemother 56 (2012), 2231–2236.
70. [70] Farrell, D.J., Castanheira, M., Mendes, R.E., Sader, H.S., Jones, R.N., In vitro activity of ceftaroline against multidrug-resistant Staphylococcus aureus and Streptococcus pneumoniae: a review of published studies and the AWARE Surveillance Program (2008–2010). Clin Infect Dis 55:Suppl. 3 (2012), S206–14.
71. [71] Tattevin, P., Boutoille, D., Vitrat, V., Van Grunderbeeck, N., Revest, M., Dupont, M., et al. Salvage treatment of methicillin-resistant staphylococcal endocarditis with ceftaroline: a multicenter observational study. J Antimicrob Chemother 69 (2014), 2010–2013.
72. [72] Saravolatz, L., Pawlak, J., Johnson, L., In vitro activity of ceftaroline against community associated methicillin-resistant, vancomycin-intermediate, vancomycin-resistant, and daptomycin-nonsusceptible Staphylococcus aureus isolates. Antimicrob Agents Chemother 54 (2010), 3027–3030.
73. [73] Shaw, K.J., Poppe, S., Schaadt, R., Brown-Driver, V., Finn, J., Pillar, C.M., et al. In vitro activity of TR-700, the antibacterial moiety of the prodrug TR-701, against linezolid-resistant strains. Antimicrob Agents Chemother 52 (2008), 4442–4447.
74. [74] Zhanel, G.G., Love, R., Adam, H., Golden, A., Zelenitsky, S., Schweizer, F., et al. Tedizolid: a novel oxazolidinone with potent activity against multidrug-resistant Gram-positive pathogens. Drugs 75 (2015), 253–270.
75. [75] Noel, G.J., Draper, M.P., Hait, H., Tanaka, S.K., Arbeit, R.D., A randomized, evaluator-blind, phase 2 study comparing the safety and efficacy of omadacycline to those of linezolid for treatment of complicated skin and skin structure infections. Antimicrob Agents Chemother 56 (2012), 5650–5654.
76. [76] Russo, A., Concia, E., Cristini, F., De Rosa, F.G., Esposito, S., Menichetti, F., et al. Current and future trends in antibiotic therapy of acute bacterial skin and skin-structure infections. Clin Microbiol Infect 22:Suppl. 2 (2016), S27–36.
77. [77] Esposito, S., Noviello, S., Leone, S., Epidemiology and microbiology of skin and soft tissue infections. Curr Opin Infect Dis 29 (2016), 109–115.
78. [78] Lipsky, B.A., Moran, G.J., Napolitano, L.M., Vo, L., Nicholson, S., Kim, M., A prospective, multicenter, observational study of complicated skin and soft tissue infections in hospitalized patients: clinical characteristics, medical treatment, and outcomes. BMC Infect Dis, 12, 2012, 227.
79. [79] Esposito, S., Bassetti, M., Borre, S., Bouza, E., Dryden, M., Fantoni, M., et al. Diagnosis and management of skin and soft-tissue infections (SSTI): a literature review and consensus statement on behalf of the Italian Society of Infectious Diseases and International Society of Chemotherapy. J Chemother 23 (2011), 251–262.
80. [80] Moran, G.J., Abrahamian, F.M., Lovecchio, F., Talan, D.A., Acute bacterial skin infections: developments since the 2005 Infectious Disease Society of America (IDSA) guidelines. J Emerg Med 44 (2013), e397–412.
81. [81] Grim, S.A., Rapp, R.P., Martin, C.A., Evans, M.E., Trimethoprim–sulfamethoxazole as a viable treatment option for infections caused by methicillin-resistant Staphylococcus aureus. Pharmacotherapy 25 (2005), 253–264.
82. [82] Corey, G.R., Wilcox, M.H., Talbot, G.H., Thye, D., Friedland, D., Baculik, T., CANVAS 1: the first phase III, randomized, double-blind study evaluating ceftaroline fosamil for the treatment of patients with complicated skin and skin structure infections. J Antimicrob Chemother 65:Suppl. 4 (2010), iv41–51.
83. [83] Wilcox, M.H., Corey, G.R., Talbot, G.H., Thye, D., Friedland, D., Baculik, T., CANVAS 2: the second phase III, randomized, double-blind study evaluating ceftaroline fosamil for the treatment of patients with complicated skin and skin structure infections. J Antimicrob Chemother 65:Suppl. 4 (2010), iv53–65.
84. [84] Yue, J., Dong, B.R., Yang, M., Chen, X., Wu, T., Liu, G.J., Linezolid versus vancomycin for skin and soft tissue infections. Cochrane Database Syst Rev(7), 2013, CD008056.
85. [85] National Institute for Health and Clinical Excellence, Surgical site infections: prevention and treatment of surgical site infection. 2016, NICE, London, UK http://www.nice.org.uk/nicemedia/pdf/CG74FullGuideline.pdf [accessed 16.08.16].
86. [86] Sharpe, J.N., Shively, E.H., Polk, H.C. Jr., Clinical and economic outcomes of oral linezolid versus intravenous vancomycin in the treatment of MRSA-complicated, lower-extremity skin and soft-tissue infections caused by methicillin-resistant Staphylococcus aureus. Am J Surg 189 (2005), 425–428.
87. [87] Stryjewski, M.E., Graham, D.R., Wilson, S.E., O'Riordan, W., Young, D., Lentnek, A., et al. Telavancin versus vancomycin for the treatment of complicated skin and skin structure infections caused by Gram-positive organisms. Clin Infect Dis 46 (2008), 1683–1693.
88. [88] Belley, A., McKay, G.A., Arhin, F.F., Sarmiento, I., Beaulieu, S., Fadhil, I., et al. Oritavancin disrupts membrane integrity of Staphylococcus aureus and vancomycin-resistant enterococci to effect rapid bacterial killing. Antimicrob Agents Chemother 54 (2010), 5369–5371.
89. [89] Zhanel, G.G., Schweizer, F., Karlowsky, J.A., Oritavancin: mechanism of action. Clin Infect Dis 54:Suppl. 3 (2012), S214–9.
90. [90] Chen, A.Y., Zervos, M.J., Vazquez, J.A., Dalbavancin: a novel antimicrobial. Int J Clin Pract 61 (2007), 853–863.
91. [91] Mendes, R.E., Tsakris, A., Sader, H.S., Jones, R.N., Biek, D., McGhee, P., et al. Characterization of methicillin-resistant Staphylococcus aureus displaying increased MICs of ceftaroline. J Antimicrob Chemother 67 (2012), 1321–1324.
92. [92] Kullar, R., Sakoulas, G., Deresinski, S., van Hal, S.J., When sepsis persists: a review of MRSA bacteraemia salvage therapy. J Antimicrob Chemother 71 (2016), 576–586.
93. [93] Mermel, L.A., Allon, M., Bouza, E., Craven, D.E., Flynn, P., O'Grady, N.P., et al. Clinical practice guidelines for the diagnosis and management of intravascular catheter-related infection: 2009 update by the Infectious Diseases Society of America. Clin Infect Dis 49 (2009), 1–45.
94. [94] Murray, K.P., Zhao, J.J., Davis, S.L., Kullara, R., Jaye, K.S., Lephart, P., et al. Early use of daptomycin versus vancomycin for methicillin-resistant Staphylococcus aureus bacteremia with vancomycin minimum inhibitory concentration >1 mg/L: a matched cohort study. Clin Infect Dis 56 (2013), 1562–1569.
95. [95] Moore, C.L., Osaki-Kiyan, P., Haque, N.Z., Perri, M.B., Donabedian, S., Zervos, M.J., Daptomycin versus vancomycin for bloodstream infections due to methicillin-resistant Staphylococcus aureus with a high vancomycin minimum inhibitory concentration: a case–control study. Clin Infect Dis 54 (2012), 51–58.
96. [96] Schwalm, J.D., El-Helou, P., Lee, C.H., Clinical outcome with oral linezolid and rifampin following recurrent methicillin-resistant Staphylococcus aureus bacteremia despite prolonged vancomycin treatment. Can J Infect Dis Med Microbiol 15 (2004), 97–100.
97. [97] Jang, H.C., Kim, S.H., Kim, K.H., Kim, C.J., Lee, S., Song, K.H., et al. Salvage treatment for persistent methicillin-resistant Staphylococcus aureus bacteremia: efficacy of linezolid with or without carbapenem. Clin Infect Dis 49 (2009), 395–401.
98. [98] Park, H.J., Kim, S.H., Kim, M.J., Lee, Y.M., Park, S.Y., Moon, S.M., et al. Efficacy of linezolid-based salvage therapy compared with glycopeptide-based therapy in patients with persistent methicillin-resistant Staphylococcus aureus bacteremia. J Infect 65 (2012), 505–512.
99. [99] Fu, J., Ye, X., Chen, C., Chen, S., The efficacy and safety of linezolid and glycopeptides in the treatment of Staphylococcus aureus infections. PLoS One, 8, 2013, e58240.
100. [100] Shorr, A.F., Kunkel, M.J., Kollef, M., Linezolid versus vancomycin for Staphylococcus aureus bacteraemia: pooled analysis of randomized studies. J Antimicrob Chemother 56 (2005), 923–929.
101. [101] http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/DrugSafetyInformationforHeathcareProfessionals/ucm085249.htm. Last accessed 21 september 2016.
102. [102] Ho, T.T., Cadena, J., Childs, L.M., Gonzalez-Velez, M., Lewis, J.S. II, Methicillin-resistant Staphylococcus aureus bacteraemia and endocarditis treated with ceftaroline salvage therapy. J Antimicrob Chemother 67 (2012), 1267–1270.
103. [103] Lin, J.C., Aung, G., Thomas, A., Jahng, M., Johns, S., Fierer, J., The use of ceftaroline fosamil in methicillin-resistant Staphylococcus aureus endocarditis and deep-seated MRSA infections: a retrospective case series of 10 patients. J Infect Chemother 19 (2013), 42–49.
104. [104] Najjar, S., Biehle, L., Najjar, J., Finkel, D., Treatment of methicillin-resistant Staphylococcus aureus bacteremia and prosthetic valve endocarditis with ceftaroline. Infect Dis Clin Pract, 22, 2014, 108.
105. [105] Oltolini, C., Castiglioni, B., Tassan Din, C., Castiglioni, A., Ossi, C., La Canna, G., Pajoro, U., Scarpellini, P., Meticillin-resistant Staphylococcus aureus endocarditis: first report of daptomycin plus ceftobiprole combination as salvage therapy. Int. J. Antimicrob. Agents 47:6 (2016), 502–504.
106. [106] Stryjewski, M.E., Lentnek, A., O'Riordan, W., Pullman, J., Tambyah, P.A., Miró, J.M., et al. A randomized phase 2 trial of telavancin versus standard therapy in patients with uncomplicated Staphylococcus aureus bacteremia: the ASSURE study. BMC Infect Dis, 14, 2014, 289.
107. [107] Lew, D.P., Waldvogel, F.A., Osteomyelitis. Lancet 364 (2004), 369–379.
108. [108] Costerton, W., Veeh, R., Shirtliff, M., Pasmore, M., Post, C., Ehrlich, G., The application of biofilm science to the study and control of chronic bacterial infections. J Clin Invest 112 (2003), 1466–1477.
109. [109] Perlroth, J., Kuo, M., Tan, J., Bayer, A.S., Miller, L.G., Adjunctive use of rifampin for the treatment of Staphylococcus aureus infections: a systematic review of the literature. Arch Intern Med 168 (2008), 805–819.
110. [110] Bernard, L., El-Hajj, Pron, B., Lotthé, A., Gleizes, V., Signoret, F., et al. Outpatient parenteral antimicrobial therapy (OPAT) for the treatment of osteomyelitis: evaluation of efficacy, tolerance and cost. J Clin Pharm Ther 26 (2001), 445–451.
111. [111] Byren, I., Rege, S., Campanaro, E., Yankelev, S., Anastasiou, D., Kuropatkin, G., et al. Randomized controlled trial of the safety and efficacy of daptomycin versus standard-of-care therapy for management of patients with osteomyelitis associated with prosthetic devices undergoing two-stage revision arthroplasty. Antimicrob Agents Chemother 56 (2012), 5626–5632.
112. [112] Parra-Ruiz, J., Vidaillac, C., Rose, W.E., Rybak, M.J., Activities of high-dose daptomycin, vancomycin, and moxifloxacin alone or in combination with clarithromycin or rifampin in a novel in vitro model of Staphylococcus aureus biofilm. Antimicrob Agents Chemother 54 (2010), 4329–4334.
113. [113] Niska, J.A., Shahbazian, J.H., Ramos, R.I., Francis, K.P., Bernthal, N.M., Miller, L.S., Vancomycin–rifampin combination therapy has enhanced efficacy against an experimental Staphylococcus aureus prosthetic joint infection. Antimicrob Agents Chemother 57 (2013), 5080–5086.
114. [114] Rayner, C.R., Baddour, L.M., Birmingham, M.C., Norden, C., Meagher, A.K., Schentag, J.J., Linezolid in the treatment of osteomyelitis: results of a compassionate use experience. Infection 32 (2004), 8–14.
115. [115] Falagas, M.E., Siempos, I.I., Papagelopoulos, P.J., Vardakas, K.Z., Linezolid for the treatment of adults with bone and joint infections. Int J Antimicrob Agents 29 (2007), 233–239.
116. [116] Tremblay, S., Lau, T.T., Ensom, M.H., Addition of rifampin to vancomycin for methicillin-resistant Staphylococcus aureus infections: what is the evidence?. Ann Pharmacother 47 (2013), 1045–1054.
117. [117] Wunderink, R.G., Niederman, M.S., Kollef, M.H., Shorr, A.F., Kunkel, M.J., Baruch, A., et al. Linezolid in methicillin-resistant Staphylococcus aureus nosocomial pneumonia: a randomized controlled trial. Clin Infect Dis 54 (2012), 621–629.
118. [118] Jiang, H., Tang, R.N., Wang, J., Linezolid versus vancomycin or teicoplanin for nosocomial pneumonia: meta-analysis of randomised controlled trials. Eur J Clin Microbiol Infect Dis 32 (2013), 1121–1128.
119. [119] Kalil, A.C., Klompas, M., Haynatzki, G., Rupp, M.E., Treatment of hospital-acquired pneumonia with linezolid or vancomycin: a systematic review and meta-analysis. BMJ Open, 3, 2013, e003912.
120. [120] Kalil, A.C., Murthy, M.H., Hermsen, E.D., Neto, F.K., Sun, J., Rupp, M.E., Linezolid versus vancomycin or teicoplanin for nosocomial pneumonia: a systematic review and meta-analysis. Crit Care Med 38 (2010), 1802–1808.
121. [121] Walkey, A.J., O'Donnell, M.R., Wiener, R.S., Linezolid vs glycopeptide antibiotics for the treatment of suspected methicillin-resistant Staphylococcus aureus nosocomial pneumonia: a meta-analysis of randomized controlled trials. Chest 139 (2011), 1148–1155.
122. [122] Bhan, U., Podsiad, A.B., Kovach, M.A., Ballinger, M.N., Keshamouni, V., Standiford, T.J., Linezolid has unique immunomodulatory effects in post-influenza community acquired MRSA pneumonia. PLoS One, 10, 2015, e0114574.